Selected research
Market Structure
Global AI In Drug Development Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global AI In Drug Development market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for AI In Drug Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for AI In Drug Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for AI In Drug Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for AI In Drug Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of AI In Drug Development include Pfizer, AstraZeneca, Johnson & Johnson, Novartis, Sanofi, Roche, Insilico Medicine, Exscientia and BenevolentAI, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global AI In Drug Development market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of AI In Drug Development and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents AI In Drug Development revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the AI In Drug Development market size, projected growth trends, production technologies, key applications, and end-use industries.
AI In Drug Development Segment by Company
Pfizer
AstraZeneca
Johnson & Johnson
Novartis
Sanofi
Roche
Insilico Medicine
Exscientia
BenevolentAI
Recursion Pharmaceuticals
Atomwise
Isomorphic Labs
XtalPi
Deep Genomics
Relay Therapeutics
AI In Drug Development Segment by Type
Software
Services
AI In Drug Development Segment by Application
Biopharmaceuticals
Synthetic Pharmaceuticals
Others
AI In Drug Development Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI In Drug Development market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AI In Drug Development and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI In Drug Development.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of AI In Drug Development in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AI In Drug Development industry.
Chapter 3: Detailed analysis of AI In Drug Development companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, AI In Drug Developmentrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Software
- Services
Applications
- Biopharmaceuticals
- Synthetic Pharmaceuticals
- Others
Companies covered
- Pfizer
- AstraZeneca
- Johnson & Johnson
- Novartis
- Sanofi
- Roche
- Insilico Medicine
- Exscientia
- BenevolentAI
- Recursion Pharmaceuticals
- Atomwise
- Isomorphic Labs
- XtalPi
- Deep Genomics
- Relay Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global AI In Drug Development Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Software
- 1.2.3 Services
- 1.3 Market Analysis by Application
- 1.3.1 Global AI In Drug Development Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Biopharmaceuticals
- 1.3.3 Synthetic Pharmaceuticals
- 1.3.4 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global AI In Drug Development Growth Trends by Region
- 1.5.1 Global AI In Drug Development Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 AI In Drug Development Market Size by Region (2021-2026)
- 1.5.3 AI In Drug Development Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global AI In Drug Development Market Dynamics
- 2.1 AI In Drug Development Industry Trends
- 2.2 AI In Drug Development Industry Drivers
- 2.3 AI In Drug Development Industry Opportunities and Challenges
- 2.4 AI In Drug Development Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global AI In Drug Development Revenue by Company (2021-2026)
- 3.2 Global AI In Drug Development Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global AI In Drug Development Key Company Head office and Area Served
- 3.4 Global AI In Drug Development Company, Product Type & Application
- 3.5 Global AI In Drug Development Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global AI In Drug Development Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 AI In Drug Development Players Market Share by Revenue in 2025
- 3.6.3 2025 AI In Drug Development Tier 1, Tier 2, and Tier 3
4 AI In Drug Development Market by Type
- 4.1 Global AI In Drug Development Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global AI In Drug Development Market Size by Type (2021-2032)
- 4.3 Global AI In Drug Development Market Size Share by Type (2021-2032)
5 AI In Drug Development Market by Application
- 5.1 Global AI In Drug Development Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global AI In Drug Development Market Size by Application (2021-2032)
- 5.3 Global AI In Drug Development Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Pfizer
- 6.1.1 Pfizer Company Information
- 6.1.2 Pfizer Business Overview
- 6.1.3 Pfizer AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Pfizer AI In Drug Development Product Portfolio
- 6.1.5 Pfizer Recent Developments
- 6.2 AstraZeneca
- 6.2.1 AstraZeneca Company Information
- 6.2.2 AstraZeneca Business Overview
- 6.2.3 AstraZeneca AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 AstraZeneca AI In Drug Development Product Portfolio
- 6.2.5 AstraZeneca Recent Developments
- 6.3 Johnson & Johnson
- 6.3.1 Johnson & Johnson Company Information
- 6.3.2 Johnson & Johnson Business Overview
- 6.3.3 Johnson & Johnson AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Johnson & Johnson AI In Drug Development Product Portfolio
- 6.3.5 Johnson & Johnson Recent Developments
- 6.4 Novartis
- 6.4.1 Novartis Company Information
- 6.4.2 Novartis Business Overview
- 6.4.3 Novartis AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Novartis AI In Drug Development Product Portfolio
- 6.4.5 Novartis Recent Developments
- 6.5 Sanofi
- 6.5.1 Sanofi Company Information
- 6.5.2 Sanofi Business Overview
- 6.5.3 Sanofi AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Sanofi AI In Drug Development Product Portfolio
- 6.5.5 Sanofi Recent Developments
- 6.6 Roche
- 6.6.1 Roche Company Information
- 6.6.2 Roche Business Overview
- 6.6.3 Roche AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Roche AI In Drug Development Product Portfolio
- 6.6.5 Roche Recent Developments
- 6.7 Insilico Medicine
- 6.7.1 Insilico Medicine Company Information
- 6.7.2 Insilico Medicine Business Overview
- 6.7.3 Insilico Medicine AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Insilico Medicine AI In Drug Development Product Portfolio
- 6.7.5 Insilico Medicine Recent Developments
- 6.8 Exscientia
- 6.8.1 Exscientia Company Information
- 6.8.2 Exscientia Business Overview
- 6.8.3 Exscientia AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Exscientia AI In Drug Development Product Portfolio
- 6.8.5 Exscientia Recent Developments
- 6.9 BenevolentAI
- 6.9.1 BenevolentAI Company Information
- 6.9.2 BenevolentAI Business Overview
- 6.9.3 BenevolentAI AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 BenevolentAI AI In Drug Development Product Portfolio
- 6.9.5 BenevolentAI Recent Developments
- 6.10 Recursion Pharmaceuticals
- 6.10.1 Recursion Pharmaceuticals Company Information
- 6.10.2 Recursion Pharmaceuticals Business Overview
- 6.10.3 Recursion Pharmaceuticals AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Recursion Pharmaceuticals AI In Drug Development Product Portfolio
- 6.10.5 Recursion Pharmaceuticals Recent Developments
- 6.11 Atomwise
- 6.11.1 Atomwise Company Information
- 6.11.2 Atomwise Business Overview
- 6.11.3 Atomwise AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Atomwise AI In Drug Development Product Portfolio
- 6.11.5 Atomwise Recent Developments
- 6.12 Isomorphic Labs
- 6.12.1 Isomorphic Labs Company Information
- 6.12.2 Isomorphic Labs Business Overview
- 6.12.3 Isomorphic Labs AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Isomorphic Labs AI In Drug Development Product Portfolio
- 6.12.5 Isomorphic Labs Recent Developments
- 6.13 XtalPi
- 6.13.1 XtalPi Company Information
- 6.13.2 XtalPi Business Overview
- 6.13.3 XtalPi AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 XtalPi AI In Drug Development Product Portfolio
- 6.13.5 XtalPi Recent Developments
- 6.14 Deep Genomics
- 6.14.1 Deep Genomics Company Information
- 6.14.2 Deep Genomics Business Overview
- 6.14.3 Deep Genomics AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Deep Genomics AI In Drug Development Product Portfolio
- 6.14.5 Deep Genomics Recent Developments
- 6.15 Relay Therapeutics
- 6.15.1 Relay Therapeutics Company Information
- 6.15.2 Relay Therapeutics Business Overview
- 6.15.3 Relay Therapeutics AI In Drug Development Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Relay Therapeutics AI In Drug Development Product Portfolio
- 6.15.5 Relay Therapeutics Recent Developments
7 North America
- 7.1 North America AI In Drug Development Market Size (2021-2032)
- 7.2 North America AI In Drug Development Market Size by Type
- 7.2.1 North America AI In Drug Development Market Size by Type (2021-2026)
- 7.2.2 North America AI In Drug Development Market Size by Type (2027-2032)
- 7.2.3 North America AI In Drug Development Market Share by Type (2021-2032)
- 7.3 North America AI In Drug Development Market Size by Application
- 7.3.1 North America AI In Drug Development Market Size by Application (2021-2026)
- 7.3.2 North America AI In Drug Development Market Size by Application (2027-2032)
- 7.3.3 North America AI In Drug Development Market Share by Application (2021-2032)
- 7.4 North America AI In Drug Development Market Size by Country
- 7.4.1 North America AI In Drug Development Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America AI In Drug Development Market Size by Country (2021-2026)
- 7.4.3 North America AI In Drug Development Market Size by Country (2027-2032)
- 7.4.4 North America AI In Drug Development Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe AI In Drug Development Market Size (2021-2032)
- 8.2 Europe AI In Drug Development Market Size by Type
- 8.2.1 Europe AI In Drug Development Market Size by Type (2021-2026)
- 8.2.2 Europe AI In Drug Development Market Size by Type (2027-2032)
- 8.2.3 Europe AI In Drug Development Market Share by Type (2021-2032)
- 8.3 Europe AI In Drug Development Market Size by Application
- 8.3.1 Europe AI In Drug Development Market Size by Application (2021-2026)
- 8.3.2 Europe AI In Drug Development Market Size by Application (2027-2032)
- 8.3.3 Europe AI In Drug Development Market Share by Application (2021-2032)
- 8.4 Europe AI In Drug Development Market Size by Country
- 8.4.1 Europe AI In Drug Development Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe AI In Drug Development Market Size by Country (2021-2026)
- 8.4.3 Europe AI In Drug Development Market Size by Country (2027-2032)
- 8.4.4 Europe AI In Drug Development Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China AI In Drug Development Market Size (2021-2032)
- 9.2 China AI In Drug Development Market Size by Type
- 9.2.1 China AI In Drug Development Market Size by Type (2021-2026)
- 9.2.2 China AI In Drug Development Market Size by Type (2027-2032)
- 9.2.3 China AI In Drug Development Market Share by Type (2021-2032)
- 9.3 China AI In Drug Development Market Size by Application
- 9.3.1 China AI In Drug Development Market Size by Application (2021-2026)
- 9.3.2 China AI In Drug Development Market Size by Application (2027-2032)
- 9.3.3 China AI In Drug Development Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia AI In Drug Development Market Size (2021-2032)
- 10.2 Asia AI In Drug Development Market Size by Type
- 10.2.1 Asia AI In Drug Development Market Size by Type (2021-2026)
- 10.2.2 Asia AI In Drug Development Market Size by Type (2027-2032)
- 10.2.3 Asia AI In Drug Development Market Share by Type (2021-2032)
- 10.3 Asia AI In Drug Development Market Size by Application
- 10.3.1 Asia AI In Drug Development Market Size by Application (2021-2026)
- 10.3.2 Asia AI In Drug Development Market Size by Application (2027-2032)
- 10.3.3 Asia AI In Drug Development Market Share by Application (2021-2032)
- 10.4 Asia AI In Drug Development Market Size by Country
- 10.4.1 Asia AI In Drug Development Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia AI In Drug Development Market Size by Country (2021-2026)
- 10.4.3 Asia AI In Drug Development Market Size by Country (2027-2032)
- 10.4.4 Asia AI In Drug Development Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa AI In Drug Development Market Size (2021-2032)
- 11.2 South America, Middle East & Africa AI In Drug Development Market Size by Type
- 11.2.1 South America, Middle East & Africa AI In Drug Development Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa AI In Drug Development Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa AI In Drug Development Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa AI In Drug Development Market Size by Application
- 11.3.1 South America, Middle East & Africa AI In Drug Development Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa AI In Drug Development Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa AI In Drug Development Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa AI In Drug Development Market Size by Country
- 11.4.1 South America, Middle East & Africa AI In Drug Development Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa AI In Drug Development Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa AI In Drug Development Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa AI In Drug Development Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst